Main description:

Therapeutic options for patients with myeloma have dramatically changed over the past 10 years. Beginning with the advances in therapy resulting from the use of high-dose therapy and autologous bone marrow or stem cell tra- plant, we have more than doubled the median survival for patients as a whole, and have now have a wealth of different biology -based treatment approaches for our patients in all disease stages. This book represents state-of-the-art information from many of the leaders in the plasma cell disorders world. Sections focusing on disease pathogenesis and biology, chemotherapy-based approaches, immune -based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders provides a comprehensive collection and an excellent resource in this time of rapid change in clinical and preclinical disease knowledge. It is important to realize that these changes did not occur in a vacuum. Partnerships between academic institutions, the pharmaceutical industry, patient advocacy groups, the National Cancer Institute, community onco- gists, and ultimately our patients worked closely together to realize these advances, and to effect the radical changes in therapy we have witnessed over the past few years. This book would not have been possible without contri- tions from each of the gifted scientists and clinicians who worked tirelessly to prepare their individual chapters all the while maintaining commitment to the scientific and clinical mission of advancing care.

Contents:

Section 1: Biologic Considerations and Myeloma

Staging and Myeloma L.T. Heffner MD

Epidemiology of Multiple Myeloma A.A Langston MD and Dixil Francis

Basic Biology of Plasma Cell Dyscrasias Kenneth Anderson MD, DFCI and Marc S. Raab

Biology Based Classification and Staging of Multiple Myeloma Peter Leif Bergsagel MD and Wee Joo Chng, MD

The importance of FISH and Cytogenetics R. Fonseca MD, Esteban Braggio and Michael Sebag

Section 2: Historical and Cytotoxic Agent based Therapies for Myeloma

Role of Autologous Stem Cell Transplantation In Multiple Myeloma J.L. Harrouseau, MD

Maintenance Therapy In Multiple Myeloma Jonathan L. Kaufman MD, Ronald Mihelic PharmD, and Sagar Lonial, MD

Therapy for Patients not Eligible for Autologous Transplant Antonio Palumbo, MD and Sara Bringhen, MD

Current Role of Anthracyclines in the Treatment of Multiple Myelma, A. Chanan-Khan, MD and Sikander Ailawadhi

Section 3: Immune Based Therapies

Allogeneic Transplantation for Multiple Myeloma Edmund K. Waller MD, PhD Fengrong Wang, MD

Immunobiology and Immunotherapy of Multiple Myeloma Madhav Dhodapkar MD

Antibody and other Immune based therapies for Myeloma N Munshi MD, DFCI

Section 4: Existing novel agents

Thalidomide In Relapsed Multiple Myeloma Patients Ashraf Badros MD

Thalidomide: Induction Therapy S. Vincent Rajkumar MD and Francis K. Baudi, MD

The Role of Bortezomib In the Treatment of Relapsed and Refractory Multiple Myeloma Paul G. Richardson MD, DFCI, Constantine S. Mitsiades, Robert Schlossman, Irene Ghobrial, Nikhil C. Munshi and Kenneth C. Anderson

Bortezomib As Induction Therapy In Multiple Myeloma Patients J San Miguel MD,PhD and M.V. Mateos, MD, PhD

Lenalidomide In Relapsed and Refractory Multiple Myeloma Donna M. Weber MD, Sheeba K. Thomas MD, Tiffany A. Richards, MS, ANP, AOCNP

Lenalidomide (Revlimid (R)) For Initial Therapy of Newly Diagnosed Multiple Myeloma Shaji Kumar MD

Section 5: Current and Future Targets

The Role of Heat Shock Protein 90 As A Therapeutic Target for Multiple Myeloma Constantine Mitsiades MD, DFCI, Teru Hideshima, Nikhil C. Munshi, Paul G. Richardson and Kenneth C. Anderson

The P13 Kinase/AKT Pathway As A therapeutic Target for Multiple Myeloma Donald Harvey, PharmD, Jeanine Silberman, MD and Sagar Lonial MD

The Mammalian Target of Rapamycin (mTOR) and Multiple Myeloma Patrick Frost, PhD Alan Lichtenstein, MD

CDK Inhibitors In Multiple Myeloma Yun Dai and Steven Grant MD, MCV

Fibroblast growth factor receptor 3 (FGFR3) and Multiple Myeloma (MM) Victor Hugo Jimenez-Zepeda, MD and Keith Stewart MD

Histone Deacetylase Inhibitors In Multiple Myeloma Teru Hideshima MD, PhD, DFCI

Death Receptors In Multiple Myeloma and Therapeutic Opportunities, F. Mollinedo, PhD

Proteasome Inhibitors as Therapy in Multiple Myeloma Dharminder Chauhan PhD, Ajita Singh, PhD and Kenneth Anderson, MD

Section 6: Supportive Care

Pathophysiology of Bone Disease in Multiple Myeloma Tomer M. Mark, MD and Roger N. Pearse MD, PhD

Anemia and Erythropoeitic Growth Factors in Multiple Myeloma N Raje MD, DFCI

Percutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Acute Painful Pathologic and Non-Pathologic Fractures Sandra Narayanan, MD and Frank Tong MD

The Role of Anatomic and